Diseases of Pulmonary Vasculature

Latest Features

Lung Transplantation in Pulmonary Arterial Hypertension: An Overview

Lung Transplantation in Pulmonary Arterial Hypertension: An Overview

Evaluating diagnosis and treatment options for pulmonary arterial hypertension.

Worsening Shortness of Breath in a 40-Year-Old Woman: A Case Study

Worsening Shortness of Breath in a 40-Year-Old Woman: A Case Study

A 40-year-old woman presents with worsening shortness of breath after being treated with long-acting nifedipine for 2 years.

Pulmonary Arterial Hypertension: Mechanisms of Exercise Intolerance

Pulmonary Arterial Hypertension: Mechanisms of Exercise Intolerance

Exercise intolerance is a hallmark symptom of pulmonary arterial hypertension.

Diagnostic Value of Bronchoalveolar Lavage in Idiopathic Pulmonary Fibrosis

Diagnostic Value of Bronchoalveolar Lavage in Idiopathic Pulmonary Fibrosis

The diagnostic value of bronchoalveolar lavage in idiopathic pulmonary fibrosis is evaluated.

Chronic Thromboembolic PH Diagnosis and Management Update: Expert Q&A

Chronic Thromboembolic PH Diagnosis and Management Update: Expert Q&A

Development of CTEPH is associated with traditional thrombotic risk factors, including thrombophilias and inflammatory processes.

Pulmonary Arterial Hypertension: Treatment Tailored by Race and Ethnicity

Pulmonary Arterial Hypertension: Treatment Tailored by Race and Ethnicity

Future clinical trials on pulmonary arterial hypertension should include patients from diverse racial and ethnic backgrounds.

Bronchopulmonary Dysplasia and Pulmonary Hypertension in Preterm Neonates

Bronchopulmonary Dysplasia and Pulmonary Hypertension in Preterm Neonates

The most common chronic respiratory morbidity affecting preterm neonates is bronchopulmonary dysplasia.

Pulmonary Complications After Noncardiac Surgery Ameliorated By Pulmonary Rehab

Pulmonary Complications After Noncardiac Surgery Ameliorated By Pulmonary Rehab

The risk of perioperative complications is increased by many factors in patients undergoing thoracic surgery.

Pulmonary Arterial Hypertension and Genetics: Interview With the Experts

Pulmonary Arterial Hypertension and Genetics: Interview With the Experts

James E. Loyd, MD, and Wendy Chung, MD, PhD, offer insight into the role of genetics in pulmonary arterial hypertension.

Latest News

6MWT Clinically Relevant and Appropriate Prognostic Tool for PAH

6MWT Clinically Relevant and Appropriate Prognostic Tool for PAH

The 6MWT is a clinically relevant and appropriate target for patients with pulmonary arterial hypertension.

Pulmonary Embolism Risk Prediction in Postpartum Women

Pulmonary Embolism Risk Prediction in Postpartum Women

Certain risk scores may not be reliable for predicting the presence of a pulmonary embolism in pregnant or postpartum women.

Pulmonary Hypertension Treatments Targeting NO Pathway Compared for Safety

Pulmonary Hypertension Treatments Targeting NO Pathway Compared for Safety

Several drugs may demonstrate different safety profiles and side effects that warrant a change in treatment for individuals with pulmonary hypertension.

Two 6-Minute Walk Tests Recommended for Suspected Pulmonary Hypertension

Two 6-Minute Walk Tests Recommended for Suspected Pulmonary Hypertension

To minimize the "learning effect" and improve accuracy, patients with suspected pulmonary hypertension should undergo two 6-minute walk tests.

Pulmonary Arterial Hypertension: Biomarker May Predict 5-Year Survival

Pulmonary Arterial Hypertension: Biomarker May Predict 5-Year Survival

Monitoring the plasma BNP level in individuals with pulmonary arterial hypertension may aid clinicians in therapeutic decision-making and overall prediction of 5-year survival rate.

Global Pulmonary Vascular Remodeling and Pulmonary Hypertension in Heart Failure

Global Pulmonary Vascular Remodeling and Pulmonary Hypertension in Heart Failure

Researchers discovered an association between global pulmonary vascular remodeling and pulmonary hypertension in patients with heart failure.

Assessment of Ambrisentan in Pulmonary Arterial Hypertension

Assessment of Ambrisentan in Pulmonary Arterial Hypertension

In a postmarketing surveillance study, ambrisentan demonstrated tolerability and potential effectiveness for pulmonary arterial hypertension treatment.

Intermediate-Risk Pulmonary Embolism Treatment With Dabigatran

Intermediate-Risk Pulmonary Embolism Treatment With Dabigatran

Patients diagnosed with an intermediate-risk pulmonary embolism may be able to start oral anticoagulation therapy after completing 72 hours of heparin therapy during hospitalization.

Pilot Study to Assess Effectiveness of Milrinone in Congenital Diaphragmatic Hernia

Pilot Study to Assess Effectiveness of Milrinone in Congenital Diaphragmatic Hernia

A pilot study will assess the effectiveness of milrinone in a small group of infants born with congenital diaphragmatic hernia.

Pulmonary Hypertension vs Age for Predicting Outcomes in Heart Transplant

Pulmonary Hypertension vs Age for Predicting Outcomes in Heart Transplant

Compared with age, pulmonary hypertension, right ventricular failure, and cardiopulmonary bypass time may better predict outcomes in heart transplantation.

Implantable Treprostinil Delivery System Shows Promise for Managing PAH

Implantable Treprostinil Delivery System Shows Promise for Managing PAH

Treprostinil, a prostacyclin derivative, used in an implantable delivery system may be an effective treatment alternative for pulmonary arterial hypertension.

PAH Long-Term Survival Predicted by Reliable Risk Calculator

PAH Long-Term Survival Predicted by Reliable Risk Calculator

Researchers examined the effect of riociguat compared with placebo on the REVEAL risk score and long-term outcomes for pulmonary arterial hypertension.

Smoke-Free Ordinances Lower Lung Cancer Risk

Smoke-Free Ordinances Lower Lung Cancer Risk

Smoke-free ordinances may reduce the number of lung cancer cases.

PAH: eGFR Changes May Predict Survival, Hospitalizations

PAH: eGFR Changes May Predict Survival, Hospitalizations

A decrease in baseline estimated glomerular filtration rate in PAH may be a predictor of hospitalization and mortality.

Intermediate-Risk Pulmonary Emboli: Catheter-Directed vs Systemic Thrombolysis

Intermediate-Risk Pulmonary Emboli: Catheter-Directed vs Systemic Thrombolysis

Catheter-directed thrombolysis vs systemic thrombolysis strategies show different risk outcomes for patients with intermediate-risk pulmonary embolism.

Pediatric Pulmonary Embolism: 9 Predictors Identified

Pediatric Pulmonary Embolism: 9 Predictors Identified

Several clinical predictors of pediatric pulmonary embolism have been identified.

Oral Riociguat May Have Clinical Utility in Severe Pediatric Pulmonary Arterial Hypertension

Oral Riociguat May Have Clinical Utility in Severe Pediatric Pulmonary Arterial Hypertension

Use of riociguat may be considered for severe pulmonary arterial hypertension in pediatric patients.

Balloon Pulmonary Angioplasty Improves Hemodynamics in CTEPH

Balloon Pulmonary Angioplasty Improves Hemodynamics in CTEPH

Balloon pulmonary angioplasty may improve hemodynamics in patients with CTEPH.

Impaired Cerebral Pressure-Flow Link in Pulmonary Arterial Hypertension

Impaired Cerebral Pressure-Flow Link in Pulmonary Arterial Hypertension

Patients with pulmonary arterial hypertension may have an impaired cerebral pressure-flow relationship.

Improving Pulmonary Arterial Compliance in PAH: Riociguat vs PDE5 Inhibitors

Improving Pulmonary Arterial Compliance in PAH: Riociguat vs PDE5 Inhibitors

Switching from a phosphodiesterase type 5 inhibitor to riociguat significantly improves pulmonary arterial compliance in patients with PAH.

Sign Up for Free e-Newsletters